MedPath

An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes

Completed
Conditions
Eyelash Hypotrichosis
Interventions
Drug: bimatoprost 0.03%
Registration Number
NCT01623479
Lead Sponsor
Allergan
Brief Summary

This is an observational study of patients treated with bimatoprost 0.03% (Latisse®) for at least 12 months for hypotrichosis of the eyelashes.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
585
Inclusion Criteria
  • Hypotrichosis of the eyelashes
  • Using bimatoprost ophthalmic solution 0.03% (Latisse®) for at least 12 months
Read More
Exclusion Criteria
  • Use of any over-the-counter medication(s) for eyelash growth
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Hypotrichosis of the Eyelashesbimatoprost 0.03%Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
Primary Outcome Measures
NameTimeMethod
Percentage of Subjects Satisfied With Latisse®Day 1

Overall subject satisfaction with Latisse® was assessed on a 5-point scale (Very Satisfied, Satisfied, Neutral, Unsatisfied, and Very Unsatisfied). The percentage of subjects satisfied and very satisfied is reported.

Secondary Outcome Measures
NameTimeMethod
Number of Applications of Latisse® Per WeekDay 1

Number of applications of Latisse® per week as reported by the subjects.

Percentage of Subjects Satisfied Wtih Their EyelashesDay 1

Overall subject satisfaction with their eyelashes was assessed on a 5-point scale (Very Satisfied, Satisfied, Neutral, Unsatisfied, and Very Unsatisfied). The percentage of subjects satisfied and very satisfied is reported.

© Copyright 2025. All Rights Reserved by MedPath